Indrayani Biotech Ltd Stock Falls to 52-Week Low of Rs.7.25

Recent Price Movement and Market Context

On 4 Mar 2026, Indrayani Biotech Ltd (Stock ID: 525226), operating in the Other Agricultural Products industry, recorded a day change of -7.38%, aligning with the sector’s overall decline. The floriculture sector, to which the company belongs, fell by -7.82% on the same day. The stock has been falling consecutively for three days, resulting in an 11.26% loss over this period. This recent slide has pushed the share price below all key moving averages, including the 5-day, 20-day, 50-day, 100-day, and 200-day averages, signalling sustained bearish momentum.

In comparison, the Sensex experienced a volatile session, initially opening down by 1,710.03 points but recovering 351.87 points to close at 78,880.69, down 1.69%. Despite this partial recovery, the broader market environment remains cautious, with indices such as NIFTY Realty and S&P BSE Realty also hitting new 52-week lows today.

Long-Term Performance and Valuation Metrics

Over the past year, Indrayani Biotech Ltd’s stock has delivered a negative return of -63.31%, starkly underperforming the Sensex, which posted an 8.07% gain during the same period. The stock’s 52-week high was Rs.23.49, highlighting the extent of the decline. This underperformance extends beyond the last year, with the company consistently lagging behind the BSE500 index in each of the previous three annual periods.

The company’s valuation reflects its challenging fundamentals. It currently holds a Mojo Score of 12.0 and a Mojo Grade of Strong Sell, an upgrade from the previous Sell rating on 19 Nov 2024. The Market Cap Grade stands at 4, indicating a relatively small market capitalisation compared to peers. The stock’s risk profile is elevated, trading at valuations that are considered risky relative to its historical averages.

Financial Performance and Profitability Trends

Indrayani Biotech Ltd’s financial metrics reveal significant headwinds. The company has experienced a compound annual growth rate (CAGR) decline of -196.32% in operating profits over the last five years, indicating deteriorating earnings capacity. The latest quarterly results for the period ending December 2025 showed a profit before tax (PBT) excluding other income of Rs.-0.69 crore, a steep fall of -260.47% compared to the previous period.

Profitability ratios further underscore the challenges. The average return on equity (ROE) stands at 9.27%, reflecting modest returns on shareholders’ funds. Additionally, the company’s ability to service debt is constrained, with a high Debt to EBITDA ratio of 17.89 times, signalling elevated leverage and potential liquidity concerns.

Operational Efficiency Indicators

Efficiency ratios also point to operational strain. The inventory turnover ratio for the half-year period is at a low 3.08 times, suggesting slower movement of stock. Similarly, the debtors turnover ratio is at 2.13 times, indicating extended collection periods and potential cash flow pressures.

Stock Risk and Market Sentiment

The stock’s risk profile is heightened by its negative operating profits and volatile earnings. Over the past year, profits have declined by -228%, compounding the negative returns for shareholders. The increase in pledged promoter shares to 24.56% this quarter adds another layer of caution, as higher pledged shares can signal potential financial stress or liquidity needs within the promoter group.

Sectoral and Broader Market Comparison

Within the Other Agricultural Products sector, Indrayani Biotech Ltd’s performance contrasts with the broader market trends. While the floriculture sector declined by -7.82% today, the Sensex’s partial recovery after a sharp gap down reflects mixed investor sentiment. The Sensex remains below its 50-day moving average, although the 50DMA is still above the 200DMA, indicating some underlying market resilience despite short-term volatility.

Summary of Key Metrics

To summarise, the stock’s key performance indicators as of 4 Mar 2026 are:

• New 52-week low price: Rs.7.25
• One-year stock return: -63.31%
• Five-year CAGR in operating profits: -196.32%
• Debt to EBITDA ratio: 17.89 times
• Average ROE: 9.27%
• Inventory turnover ratio (HY): 3.08 times
• Debtors turnover ratio (HY): 2.13 times
• Pledged promoter shares: 24.56%

These figures collectively illustrate the pressures faced by Indrayani Biotech Ltd, reflected in its share price reaching a new 52-week low and the company’s current Strong Sell rating.

Limited Period Only. Get Started for only Rs. 16,999 - Get MojoOne for 2 Years + 1 Year Absolutely FREE! (72% Off) Get 72% Off →